CDK5 and Huntington disease: Three weeks of roscovitine administration reduced CDK5 activity in the HD mouse brain compared with the vehicle-injected HD mouse brain (Figure 9B), while it did not change the CDK5 activity in the brain of wild-type mice (Figure S4B).